PTEN mutation

GPTKB entity

Statements (63)
Predicate Object
gptkbp:instance_of gptkb:physicist
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Endometrial_cancer
gptkbp:affects quality of life
cell growth
immune response
patient prognosis
treatment strategies
tumor suppressor gene
gptkbp:analyzes metabolic disorders
gptkbp:applies_to personalized medicine
gptkbp:associated_with gptkb:healthcare_organization
gptkbp:can_be lipomas
endometrial cancer
dysregulated signaling pathways
gptkbp:can_lead_to gptkb:Cowden_syndrome
gptkb:neurofibromatosis_type_1
gptkb:healthcare_organization
increased cell proliferation
neurodevelopmental disorders
neurocognitive disorders
increased tumor aggressiveness
gptkbp:caused_by gptkb:healthcare_organization
hamartomas
gptkbp:descendant in an autosomal dominant manner
gptkbp:focuses_on molecular diagnostics
clinical research
https://www.w3.org/2000/01/rdf-schema#label PTEN mutation
gptkbp:influence treatment response
clinical outcomes
gptkbp:is_aimed_at therapeutic agents
gptkbp:is_associated_with cellular metabolism
vascular malformations
metastasis
autism spectrum disorders
increased risk of recurrence
gptkbp:is_characterized_by loss of function
gptkbp:is_found_in various tumors
gptkbp:is_involved_in cell cycle regulation
DNA repair mechanisms
cell signaling pathways
tumorigenesis
tumor angiogenesis
cellular apoptosis
gptkbp:is_linked_to gptkb:healthcare_organization
environmental factors
genetic predisposition
hereditary cancer syndromes
gptkbp:is_part_of genetic profiling
gptkbp:is_recognized_by biopsy samples
gptkbp:is_studied_in oncology
therapeutic interventions
pharmacogenomics
gptkbp:is_tested_for tumor progression
gptkbp:recognizes genetic testing
blood samples
gptkbp:risk_factor multiple cancers
gptkbp:subject clinical trials
genetic counseling
gptkbp:targets gptkb:physicist
gptkbp:type_of somatic mutation
gptkbp:was_a_factor_in tumor microenvironment
gptkbp:was_marked_by poor prognosis